Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia
A Randomized, Phase I/II Clinical Trial Evaluating the Safety, Reactogenicity, and Immunogenicity of Licensed Trivalent Influenza Vaccine Administered With Recombinant Interferon Alpha Among Patients With Chronic Lymphocytic Leukemia
1 other identifier
interventional
N/A
0 countries
N/A
Brief Summary
The goal of this clinical study is to learn if Pegasys (pegylated interferon) or Roferon (interferon) can make the Trivalent Inactivated Influenza vaccine (TIV) more effective in increasing the body's immune reaction against the flu virus in patients with Chronic Lymphocytic Leukemia (CLL).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 19, 2009
CompletedFirst Posted
Study publicly available on registry
August 20, 2009
CompletedStudy Start
First participant enrolled
April 1, 2011
CompletedAugust 3, 2012
August 1, 2012
August 19, 2009
August 2, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Immunogenicity rate
Day 1, 8, 28, 56 and 6 Months
Study Arms (3)
TIV
EXPERIMENTALTIV (Influenza Vaccine Trivalent Inactivated) alone
TIV + PEGrIFN-α
EXPERIMENTALTIV + Pegylated Interferon
TIV + IFNα
EXPERIMENTALTIV + Interferon
Interventions
15 μg (0.5 ml) through needle into arm muscle on Days 1 and 28.
180 μg (0.5 ml) before receiving TIV, through a needle under the skin.
3 million units (0.5 ml) before receiving TIV, through a needle under the skin.
Eligibility Criteria
You may qualify if:
- Capable of understanding the protocol requirements and risks and providing written informed consent.
- Patients with histologically or cytologically confirmed diagnosis of chronic lymphocytic leukemia according to established guidelines.
- Patients with Rai stages 0 to 4.
- Age \>/= 18 years old.
- If patients have been treated with antineoplastic therapy, it must have been finished 3 months or longer prior to enrollment.
- Patients with complete or partial remission and those with stable (CLL) disease will be considered.
- Patients who have received influenza vaccine in past 4 months will also be considered.
- Patients willing to receive recombinant cytokine.
- Patient willing to receive commercially available influenza vaccine that will not provide protection against the following years of influenza strains.
- Patients must have adequate hepatic function defined as follows: total bilirubin \</= 2.0 mg/dL; SGOT and /or SGPT \</= 3 x upper normal limit of the reference laboratory value unless liver function abnormalities are considered due to underlying cancer or congenital hemolytic disorders.
- Patient should avoid H2 blockers while on study. However, if H2 blockers are required to use, this will be reported and will be taken in consideration during response rate analysis.
- Females patients who are able to have children must agrees to remain abstinent or use (or have their partner use) 2 acceptable methods of birth control during the time period starting 2 weeks prior to enrollment through 1 month from last vaccination dose. Acceptable methods of birth control are: intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge and condom. If they suspect pregnancy during the study, they must notify the study doctor.
You may not qualify if:
- Concurrent serious medical illness in the opinion of Principle Investigator that could potentially interfere with protocol compliance.
- Concurrent or previous malignancy whose prognosis is poor (\< 90% probability of survival is 5 years).
- History of known chronic viral infections within 12 months, including HIV and Hepatitis B or Hepatitis C. A screening for hepatitis or HIV will not be performed for this study.
- Positive screening pregnancy test within 2 weeks in non-menopausal women or breast-feeding.
- Patients with known allergy to either vaccine or interferon preparation.
- Patients with neutropenia (ANC \< 500 cells/uL) within 4 weeks.
- Patients with lymphocytopenia (ALC \< 300 cells/uL) within 4 weeks.
- Concomitant use of investigational vaccines and/or medications within four weeks prior to study entry, or expected use of experimental or licensed vaccines or blood/blood products prior to study completion.
- Receipt of immunoglobulin in 3 months.
- Subject is enrolled in a conflicting clinical trial.
- History of Guillain-Barre Syndrome.
- Has an acute illness including an oral temperature greater than 100.4°F, within one week of vaccination.
- In patients who have prior therapy with fludarabine or alemtuzumab (Campath®), the treatment must have completed 12 months prior to enrollment.
- In patients who have prior therapy with Rituximab (Rituxan®), the treatment must have completed 6 months prior to enrollment.
- Patients with history of medically significant psychiatric disease, especially endogenous depression (not reactive to diagnosis of cancer), psychosis and bipolar disorder.
- +4 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Amar Safdar, MD
UT MD Anderson Cancer Center
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 19, 2009
First Posted
August 20, 2009
Study Start
April 1, 2011
Last Updated
August 3, 2012
Record last verified: 2012-08